By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera said on Friday that it accepted Pfizer's $10 billion acquisition offer, in what could be the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the past week. Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, sparking a strategic fight for a coveted asset in the growing weight-loss market. Pfizer is trying to gain a toehold in that marketplace to overcome past in-house stumbles in developing weight-loss drugs. Pfizer will pay $86.25 a share in cash, a premium of 3.69% to Metsera's Friday close, according to Metsera's statement. The offer includes $65.60 a share in cash and a contingent value

See Full Page